Abstract |
BTI-322, a rat monoclonal IgG2b directed against the CD2 antigen on T cells and natural killer (NK) cells, blocks primary and memory alloantigen proliferative responses in vitro. We have evaluated the pharmacokinetics and safety of BTI-322 during treatment of 20 transplant recipients with steroid-refractory acute graft-versus-host disease (GVHD). Treatment consisted of BTI-322 by intravenous (IV) bolus or 30-minute infusion at approximately 0.1 mg/kg/d for 10 days in addition to continuing high-dose steroids and tacrolimus or cyclosporine. Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg. Ten patients experienced transient dyspnea sometimes accompanied by nausea, vomiting, diarrhea, and tachycardia shortly after the initial bolus dose of drug, but serious drug-related adverse events were not seen during the remainder of the infusions. At the end of treatment (day 11), there were six patients with complete responses and five with a reduction in grade of GVHD for a total response rate of 55% (95% confidence interval [CI], 32% to 77%). Antibodies targeting CD2 may be active in the treatment of acute GVHD, and evaluation of a humanized form of BTI-322 is warranted.
|
Authors | D Przepiorka, G L Phillips, V Ratanatharathorn, M Cottler-Fox, L H Sehn, J H Antin, D LeBherz, M Awwad, J Hope, J B McClain |
Journal | Blood
(Blood)
Vol. 92
Issue 11
Pg. 4066-71
(Dec 01 1998)
ISSN: 0006-4971 [Print] United States |
PMID | 9834211
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- CD2 Antigens
- LO-CD2a
- Steroids
|
Topics |
- Adult
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Bone Marrow Transplantation
(adverse effects)
- CD2 Antigens
(immunology)
- Drug Resistance
- Female
- Graft vs Host Disease
(drug therapy, immunology)
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Humans
- Killer Cells, Natural
(immunology)
- Male
- Middle Aged
- Rats
- Steroids
(pharmacology)
- Transplantation, Homologous
|